Inovio Pharmaceuticals, Inc. announced today that its SynConA DNA vaccine containing multiple malaria antigens delivered via its CELLECTRAA electroporation device demonstrated strong and durable antibody and T-cell immune responses in small animals and non-human primates.
http://www.benzinga.com/news/13/08/3840799/inovio-malaria-dna-vaccine-demonstrates-robust-immune-responses-in-animal-models
http://www.benzinga.com/news/13/08/3840799/inovio-malaria-dna-vaccine-demonstrates-robust-immune-responses-in-animal-models
No comments:
Post a Comment